Circulating Biomarkers of Distinct Pathophysiological Pathways in Heart Failure with Preserved vs. Reduced Left Ventricular Ejection Fraction
Population
570 patients aged ≥60 years with NYHA class ≥II from the TIME-CHF trial, including 458 with HFrEF and 112…
Design
Cohort
Follow-up
18 months
Authors
Discussion
Loading...
Member takes
Implication
May aid HF subtype phenotyping in research cohorts; leaves open whether panels alter clinical decisions or outcomes.
Structured PICO
P
Population
570 patients aged ≥60 years with NYHA class ≥II from the TIME-CHF trial, including 458 with HFrEF (LVEF ≤40%) and 112 with HFpEF (LVEF ≥50%).
O
Outcome
18-month overall and HF hospitalization-free survivalcomposite
Biomarker profiles differ significantly between HFpEF and HFrEF, reflecting distinct pathophysiological pathway activation, though their prognostic value for clinical outcomes remains largely similar.
Cite This Study
Wijk et al. (2015) studied this question.